Home Ingredients Phenylpiracetam (Phenotropil / Carphedon)
CognitiveEnergyMood & Mental HealthStress & Anxiety

Phenylpiracetam (Phenotropil / Carphedon)

Synthetic — phenyl-substituted piracetam (Russian-developed)
Evidence Level
Limited
3 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

Phenylated piracetam derivative developed in Russia (1983) by Russian Academy of Sciences for COSMONAUTS. Stimulant + cognitive effects; prescription drug in Russia for cerebrovascular deficiency, depression, asthenia, brain injury. WADA-PROHIBITED for athletic competition (only racetam on prohibited list). Effects partially via dopamine reuptake inhibition. Russian-language clinical research base; limited Western RCTs.

Studied Dose RUSSIAN: 100-200 mg/day divided morning + early afternoon. STROKE/TBI: 200-400 mg/day. Half-life ~3-5 hr. CYCLE 4-6 wk on/1-2 wk off (rapid tolerance). WADA-PROHIBITED — only racetam on list.
Active Compound Phenylpiracetam ((R,S)-2-(2-oxo-4-phenyl-1-pyrrolidinyl)acetamide, fonturacetam, carphedon, phenotropil) — phenyl-substituted piracetam with dramatically enhanced lipophilicity and stimulant properties

Benefits

Vascular encephalopathy

Gustov 2006 (Zh Nevrol Psikhiatr Im S S Korsakova 106(3):52-53, Russian-language) — phenylpiracetam reduced neurological deficits following vascular encephalopathy with improved memory, attention, and cognitive processing vs control groups. Russian clinical studies establish indication where prescribed. Limited by Russian-language literature less accessible to Western literature reviews.

Supported by Trial 1, Trial 2

Asthenia and chronic fatigue syndrome

Russian studies indicate efficacy in treating ASTHENIA, chronic fatigue syndrome, and post-TBI fatigue. Effects via combined dopaminergic stimulation and cognitive enhancement. Approved Russian indication. Most consistent clinical use case in Russian medical practice.

Supported by Trial 1, Trial 2

Cosmonaut cognitive/physical performance enhancement

ORIGINAL DEVELOPMENT PURPOSE — created by Russian Academy of Sciences in 1983 for cosmonauts during extended space missions to enhance cognitive function, physical stamina, and cold tolerance. Used by Russian space program. Demonstrates real performance enhancement effects (which led to WADA ban). Information letter from Institute of Medical-Biological Problems of Russian Academy of Sciences documents original space program use.

Supported by Trial 2, Trial 1

Cognitive impairment from organic causes

Studies in cognitive decline from organic causes (post-stroke, TBI, encephalopathy, glioma surgery) showed improvements with phenylpiracetam. Approved Russian indication. Mechanism: combined cognitive enhancement + stimulation + neuroprotection. Limited by Russian-language literature.

Supported by Trial 1, Trial 2

Anticonvulsant (epilepsy adjunct)

study showed phenylpiracetam reduced seizure frequency and improved cognitive function in epilepsy patients. Used as add-on therapy to standard antiepileptics. Mechanism unclear but consistent across studies. Approved indication in Russia for convulsive disorders.

Supported by Trial 2

Athletic performance (WADA-banned)

WADA-PROHIBITED for athletic competition under Section S6 Stimulants — the ONLY racetam on prohibited list. Olga Pyleleva (Russian Olympic athlete) lost silver medal 2006 for carphedon use; cyclist Anton Reshetnikov suspended 2 years 2007. Confirms genuine performance enhancement. NOT recommended for athletes; absolutely avoid in competition.

Supported by Trial 1

Mechanism of action

1

Dopamine reuptake inhibition (stimulant mechanism)

Phenylpiracetam inhibits dopamine reuptake — distinguishing it from other racetams. Mechanism for stimulant effects, motivation enhancement, and athletic performance benefits that led to WADA ban. Sommer 2014 showed (R)-enantiomer (MRZ-9547) significantly increases progressive ratio responding in rats — indicating motivation enhancement.

2

Multi-receptor neurotransmitter modulation

Beyond DA reuptake inhibition: modulates NMDA, GABA, serotonergic, cholinergic systems. Phenyl group dramatically enhances BBB penetration vs piracetam. Multi-target mechanism explains broad clinical effects (cognitive + stimulant + anxiolytic + neuroprotective).

3

Locomotor activity stimulation

Animal studies show significant locomotor activity increases — stimulant pharmacology resembling mild psychostimulant. R-enantiomer especially active. Mechanism for physical performance enhancement; explains WADA prohibition.

4

Cold tolerance enhancement (unique)

Original cosmonaut development purpose included cold tolerance — shown in Russian research. Mechanism via thermogenesis and stress-resistance pathways. Distinguishes phenylpiracetam from typical stimulants and racetams.

5

Neuroprotection in cerebral ischemia

Russian comparative studies (Eksperimental'naia i Klinicheskaia Farmakologiia 2007) showed phenylpiracetam provided greater neuroprotection than piracetam in cerebral ischemia models — reduced infarct volume, improved behavioral outcomes. Mechanism: enhanced potency + multi-system effects. Translation to clinical stroke use established in Russia.

Clinical trials

1
Gustov 2006 — Phenylpiracetam in Vascular Encephalopathy
PubMed

Russian-language clinical study (Gustov AA, Smirnov AA, Korotkova OV, Belyakova MV 2006, Zh Nevrol Psikhiatr Im S S Korsakova 106(3):52-53).

Patients with vascular encephalopathy receiving phenylpiracetam vs control. Memory, attention, cognitive processing, neurological deficit scores measured.

Phenylpiracetam REDUCED neurological deficits with improved memory, attention, and cognitive processing vs control groups. Russian clinical evidence base. LIMITED BY: Russian-language only (less peer review international scrutiny), limited methodological detail in available abstracts. Foundational evidence for Russian regulatory approval and clinical use in vascular cognitive impairment.

2
Lybzikova 2008 — Phenylpiracetam in Epilepsy
PubMed

Russian-language clinical study (Lybzikova GN, Iaglova ZhS, Kharlamova IuS 2008, Zh Nevrol Psikhiatr Im S S Korsakova).

Epilepsy patients given phenylpiracetam as add-on therapy. Seizure frequency and cognitive function measured.

Phenylpiracetam REDUCED frequency of seizures and IMPROVED cognitive function in absence of epileptiform EEG abnormalities. Add-on therapy benefit demonstrated. Russian-language literature with same accessibility limitations. Foundational evidence for Russian approval as anticonvulsant adjunct.

3
Zvejniece 2011 — Stereoselective Pharmacology
PubMed

Preclinical pharmacology study (Zvejniece L, Svalbe B, Veinberg G, Grinberga S, Vorona M, Kalvinsh I, Dambrova M 2011, Basic Clin Pharmacol Toxicol 109(5):407-412, doi:10.1111/j.1742-7843.2011.00742.x).

Animal studies comparing R- and S-enantiomers of phenylpiracetam (phenotropil). Locomotor activity, antidepressant effects, memory function assessed.

R-PHENOTROPIL showed significant LOCOMOTOR ACTIVITY increases at 10-50 mg/kg and ANTIDEPRESSANT effects at 50-100 mg/kg. Both enantiomers demonstrated some pharmacological activity but R-enantiomer more active for stimulant effects. Foundational stereoselective pharmacology study supporting development of selective enantiomer formulations (MRZ-9547).

Side effects and drug interactions

Common Potential side effects

STIMULANT side effects: insomnia, anxiety, restlessness, headache.
RAPID TOLERANCE — effects diminish within 1-2 weeks of continuous use; cycling required.
GI upset (nausea).
Cardiovascular: theoretical concerns at high doses (mild stimulant).
ATHLETES: WADA-PROHIBITED — will fail drug tests in competition (Section S6 Stimulants).
Pregnancy/lactation: AVOID.
Anxiety disorders, bipolar, psychosis: AVOID (stimulating, may activate symptoms).
Long-term safety with cycling: moderate Russian data.

Important Drug interactions

MAOIs: SIGNIFICANT interaction risk (dopaminergic effects).
Stimulants (caffeine, ADHD medications): additive effects.
Antidepressants: theoretical interactions; SSRIs generally compatible but monitor.
Sympathomimetic decongestants: additive cardiovascular effects.
Antiseizure medications: complex (used as adjunct in Russia despite stimulant pharmacology).
Generally compatible with most medications at appropriate doses.

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Frequently asked questions about Phenylpiracetam (Phenotropil / Carphedon)

What is Phenylpiracetam (Phenotropil / Carphedon)?

Phenylated piracetam derivative developed in Russia (1983) by Russian Academy of Sciences for COSMONAUTS.

What does Phenylpiracetam (Phenotropil / Carphedon) do?

Phenylpiracetam inhibits dopamine reuptake — distinguishing it from other racetams. Mechanism for stimulant effects, motivation enhancement, and athletic performance benefits that led to WADA ban. In clinical research, Phenylpiracetam (Phenotropil / Carphedon) has been studied for vascular encephalopathy, asthenia and chronic fatigue syndrome, cosmonaut cognitive/physical performance enhancement.

Who should take Phenylpiracetam (Phenotropil / Carphedon)?

Phenylpiracetam (Phenotropil / Carphedon) may be most relevant for people interested in cognitive, energy, mood & mental health. It has been clinically studied for vascular encephalopathy, asthenia and chronic fatigue syndrome, cosmonaut cognitive/physical performance enhancement. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Phenylpiracetam (Phenotropil / Carphedon) take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Phenylpiracetam (Phenotropil / Carphedon)?

For cognitive goals, Phenylpiracetam (Phenotropil / Carphedon) is typically taken in the morning with breakfast for sustained daytime effects. Avoid late-day dosing if it affects your sleep. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Phenylpiracetam (Phenotropil / Carphedon) worth taking?

Phenylpiracetam (Phenotropil / Carphedon) has limited clinical evidence (Evidence Level 2/5 on NutraSmarts) — preliminary research suggests potential benefit, but more rigorous trials are needed. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Phenylpiracetam (Phenotropil / Carphedon) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Phenylpiracetam (Phenotropil / Carphedon)?

The clinically studied dose for Phenylpiracetam (Phenotropil / Carphedon) is RUSSIAN: 100-200 mg/day divided morning + early afternoon. STROKE/TBI: 200-400 mg/day. Half-life ~3-5 hr. CYCLE 4-6 wk on/1-2 wk off (rapid tolerance). WADA-PROHIBITED — only racetam on list.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Phenylpiracetam (Phenotropil / Carphedon) used for?

Phenylpiracetam (Phenotropil / Carphedon) is studied for vascular encephalopathy, asthenia and chronic fatigue syndrome, cosmonaut cognitive/physical performance enhancement. Gustov 2006 (Zh Nevrol Psikhiatr Im S S Korsakova 106(3):52-53, Russian-language) — phenylpiracetam reduced neurological deficits following vascular encephalopathy with improved memory, attention, and cognitive processing vs control groups.